Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Complex immunomodulatory therapy for patients with immune thrombocytopenia (T-MEM)
2023-505788-35-00Phase 2Authorised
- Sponsor
- Fakultní nemocnice Hradec Králové
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, single-arm trial of romiplostim, eltrombopag, avatrombopag, cyclosporine, rituximab and 1 more in immune thrombocytopenia (ITP), sponsored by Fakultní nemocnice Hradec Králové. Primary endpoints: Platelet count at scheduled visits and Remission without therapy at scheduled visits. Planned start Jun 2023; status: authorised.
02
Drugs
romiplostimeltrombopagavatrombopagcyclosporinerituximab
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on 2023-505788-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505788-35-00.